{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:32:03Z","timestamp":1787909523679,"version":"build-2784847793"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"BMS","award":["Osteosimply014"],"award-info":[{"award-number":["Osteosimply014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tenofovir disoproxil fumarate, particularly when given with a ritonavir-boosted PI, reduces bone mineral density (BMD) and increases bone turnover markers (BTMs). Ritonavir-boosted atazanavir plus lamivudine is a feasible simplified option. We evaluated whether switching from a triple ritonavir-boosted PI plus tenofovir disoproxil fumarate to a two-drug regimen of lamivudine plus ritonavir-boosted atazanavir would improve BMD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Single-arm pilot study. Virologically suppressed patients on tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted PI with low BMD, without previous resistance mutations and\/or virological failure to study drugs were switched to 100\/300\u2005mg of ritonavir-boosted atazanavir plus 300\u2005mg of lamivudine once daily. The primary endpoint was BMD change by DXA at Week 48.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 31 patients, 4 (13%) female, and median age was 40\u2005years. Seven participants (22.5%) had osteoporosis. At 48\u2005weeks, mean (SD) changes in spine and hip BMD were +0.01 (0.03) (P\u200a=\u200a0.0239) and +0.013 (0.03)\u2005g\/cm2 (P\u200a=\u200a0.0046), respectively. Mean (SD) T-score changes were +0.1 (0.23) (P\u200a=\u200a0.0089) and +0.25 (0.76) (P\u200a=\u200a0.0197), respectively. N-telopeptide and urine tenofovir disoproxil fumarate toxicity markers showed significant improvements. One participant withdrew from the study and two were lost to follow-up. There were no virological failures, or serious or grade 3\u20134 adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Switching from a tenofovir disoproxil fumarate plus ritonavir-boosted PI triple therapy to a lamivudine plus ritonavir-boosted atazanavir two-drug regimen in virologically suppressed HIV-infected adults with low BMD was safe, increased low BMD and reduced plasma markers of bone turnover and urine markers of tenofovir disoproxil fumarate toxicity over 48\u2005weeks.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac137","type":"journal-article","created":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T19:06:29Z","timestamp":1650222389000},"page":"1974-1979","source":"Crossref","is-referenced-by-count":3,"title":["Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study"],"prefix":"10.1093","volume":"77","author":[{"given":"Jos\u00e9 L","family":"Blanco","sequence":"first","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhon","family":"Rojas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Subirana","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Callau","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Martinez-Rebollar","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonzalez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"2022070118464504200_dkac137-B1","article-title":"Documento de consenso sobre la osteoporosis en la infecci\u00f3n por el VIH (Mayo 2016)","year":"2016"},{"key":"2022070118464504200_dkac137-B2","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","article-title":"Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system","volume":"93","author":"Triant","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2022070118464504200_dkac137-B3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"2022070118464504200_dkac137-B4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"2022070118464504200_dkac137-B5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/COH.0000000000000271","article-title":"Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients","volume":"11","author":"Negredo","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2022070118464504200_dkac137-B6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAD.0000000000001725","article-title":"Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health","volume":"32","author":"McComsey","year":"2018","journal-title":"AIDS"},{"key":"2022070118464504200_dkac137-B7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022070118464504200_dkac137-B8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hiv.12123","article-title":"Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks","volume":"15","author":"Bloch","year":"2014","journal-title":"HIV Med"},{"key":"2022070118464504200_dkac137-B9","doi-asserted-by":"crossref","first-page":"104543","DOI":"10.1016\/j.antiviral.2019.104543","article-title":"Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1","volume":"170","author":"Eron","year":"2019","journal-title":"Antiviral Res"},{"key":"2022070118464504200_dkac137-B10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","article-title":"Lopinavir\/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)","volume":"40","author":"Arribas","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022070118464504200_dkac137-B11","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: Randomized, open-Label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022070118464504200_dkac137-B12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48\u2005week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2022070118464504200_dkac137-B13","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/jac\/dky123","article-title":"Atazanavir\/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96\u2005week outcomes of a randomized trial","volume":"73","author":"Fabbiani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022070118464504200_dkac137-B14","author":"Fracture Risk Assessment Tool - FRAX"},{"key":"2022070118464504200_dkac137-B15","article-title":"EACS Guidelines Version 11.0","author":"European ADS Society","year":"2021"},{"key":"2022070118464504200_dkac137-B16","article-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","year":"2021"},{"key":"2022070118464504200_dkac137-B17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2022070118464504200_dkac137-B18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jbmr.1874","article-title":"HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study","volume":"28","author":"Guerri-Fernandez","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2022070118464504200_dkac137-B19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"2022070118464504200_dkac137-B20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkw379","article-title":"Simplification to dual therapy (atazanavir\/ritonavir\u200a+\u200alamivudine) versus standard triple therapy [atazanavir\/ritonavir\u200a+\u200atwo nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96\u2005week results from an open-label, non-inferiority, randomized clinical trial (SALT study)","volume":"72","author":"Perez-Molina","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022070118464504200_dkac137-B21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkx068","article-title":"Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir\/ritonavir\u200a+\u200alamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial","volume":"72","author":"Lombardi","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022070118464504200_dkac137-B22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/15284336.2016.1149929","article-title":"Improvement of BMD after Switching from Lopinavir\/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir\/R Plus Lamivudine: OLE-LIP Substudy","volume":"17","author":"Crespo","year":"2016","journal-title":"HIV Clin Trials"},{"key":"2022070118464504200_dkac137-B23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiv194","article-title":"Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate\/emtricitabine plus atazanavir\/ritonavir, darunavir\/ritonavir, or raltegravir","volume":"212","author":"Brown","year":"2015","journal-title":"J Infect Dis"},{"key":"2022070118464504200_dkac137-B24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong","year":"2019","journal-title":"J Viral Hepat"},{"key":"2022070118464504200_dkac137-B25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"J Virus Erad"},{"key":"2022070118464504200_dkac137-B26","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"2022070118464504200_dkac137-B27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/jbmr.3834","article-title":"Prolonged effect of zoledronic acid on bone mineral density and turnover in HIV-infected adults on tenofovir: a randomized, open-label study","volume":"34","author":"Carr","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2022070118464504200_dkac137-B28","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/QAI.0000000000002071","article-title":"Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States","volume":"81","author":"Crane","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022070118464504200_dkac137-B29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/jit122","article-title":"Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV type 1\u2013infected patients: Week 48 results","volume":"208","author":"Gallant","year":"2013","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/7\/1974\/44373735\/dkac137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/7\/1974\/44373735\/dkac137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T18:47:26Z","timestamp":1656701246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/7\/1974\/6580673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,5,5]]},"published-print":{"date-parts":[[2022,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac137","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,5]]}}}